These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22761336)

  • 1. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition.
    Wang Y; Huang JW; Calses P; Kemp CJ; Taniguchi T
    Cancer Res; 2012 Aug; 72(16):4037-46. PubMed ID: 22761336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [RAD51 regulates REV1 recruitment to DNA double-strand
    break sites].
    Huang M; Yang YR; Sun XY; Zhang T; Guo CX
    Yi Chuan; 2018 Nov; 40(11):1007-1014. PubMed ID: 30465533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity.
    Huang JW; Wang Y; Dhillon KK; Calses P; Villegas E; Mitchell PS; Tewari M; Kemp CJ; Taniguchi T
    Mol Cancer Res; 2013 Dec; 11(12):1564-73. PubMed ID: 24088786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
    Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
    Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
    Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.
    Gasparini P; Lovat F; Fassan M; Casadei L; Cascione L; Jacob NK; Carasi S; Palmieri D; Costinean S; Shapiro CL; Huebner K; Croce CM
    Proc Natl Acad Sci U S A; 2014 Mar; 111(12):4536-41. PubMed ID: 24616504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.
    Song L; McNeil EM; Ritchie AM; Astell KR; Gourley C; Melton DW
    BMC Cancer; 2017 Dec; 17(1):864. PubMed ID: 29254481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
    Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
    J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-34s negatively regulate homologous recombination through targeting RAD51.
    Chen S; Liu R; Wang Q; Qi Z; Hu Y; Zhou P; Wang Z
    Arch Biochem Biophys; 2019 May; 666():73-82. PubMed ID: 30951682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
    Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
    Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
    [No Abstract]   [Full Text] [Related]  

  • 14. REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks.
    Chatterjee N; Whitman MA; Harris CA; Min SM; Jonas O; Lien EC; Luengo A; Vander Heiden MG; Hong J; Zhou P; Hemann MT; Walker GC
    Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28918-28921. PubMed ID: 33168727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
    Johnson N; Johnson SF; Yao W; Li YC; Choi YE; Bernhardy AJ; Wang Y; Capelletti M; Sarosiek KA; Moreau LA; Chowdhury D; Wickramanayake A; Harrell MI; Liu JF; D'Andrea AD; Miron A; Swisher EM; Shapiro GI
    Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17041-6. PubMed ID: 24085845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
    Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
    Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential roles for DNA polymerases eta, zeta, and REV1 in lesion bypass of intrastrand versus interstrand DNA cross-links.
    Hicks JK; Chute CL; Paulsen MT; Ragland RL; Howlett NG; Guéranger Q; Glover TW; Canman CE
    Mol Cell Biol; 2010 Mar; 30(5):1217-30. PubMed ID: 20028736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
    Shi Y; Jin J; Wang X; Ji W; Guan X
    Neoplasia; 2019 Jun; 21(6):533-544. PubMed ID: 31029033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.